Welcome to LookChem.com Sign In|Join Free

CAS

  • or

28002-70-2

Post Buying Request

28002-70-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

28002-70-2 Usage

Description

Neomycin B sulphate is an aminoglycoside antibiotic that exhibits broad-spectrum antimicrobial activity against a variety of bacterial infections. It functions by inhibiting bacterial protein synthesis, leading to their death. Neomycin B sulphate is not systemically absorbed when applied topically or taken orally, making it suitable for localized infections and reducing the risk of systemic side effects. However, it should be used with caution to prevent allergic reactions and the emergence of antibiotic-resistant bacterial strains.

Uses

Used in Pharmaceutical Industry:
Neomycin B sulphate is used as a topical and oral antibiotic for treating various skin, ear, and eye infections. Its application reason is its broad-spectrum antimicrobial activity and minimal systemic absorption, which allows for effective treatment of localized infections while reducing the risk of systemic side effects.
Used in Cosmetic Industry:
Neomycin B sulphate is used as a preservative in cosmetic products to prevent microbial contamination and ensure product safety. Its application reason is its broad-spectrum antimicrobial activity and compatibility with various cosmetic formulations.
Used in Veterinary Medicine:
Neomycin B sulphate is used as an antibiotic in veterinary medicine to treat bacterial infections in animals. Its application reason is its effectiveness against a wide range of bacterial pathogens and minimal risk of systemic side effects when administered appropriately.
Used in Agricultural Industry:
Neomycin B sulphate is used as an antimicrobial agent in agriculture to control bacterial infections in crops and livestock. Its application reason is its broad-spectrum antimicrobial activity and potential to reduce the spread of bacterial diseases in agricultural settings.

Check Digit Verification of cas no

The CAS Registry Mumber 28002-70-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,0,0 and 2 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 28002-70:
(7*2)+(6*8)+(5*0)+(4*0)+(3*2)+(2*7)+(1*0)=82
82 % 10 = 2
So 28002-70-2 is a valid CAS Registry Number.

28002-70-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol,sulfuric acid

1.2 Other means of identification

Product number -
Other names Framycetin sulfate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:28002-70-2 SDS

28002-70-2Upstream product

28002-70-2Relevant articles and documents

METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS

-

, (2021/03/13)

In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

Method for apparatus for a defined serumfree medical solution useful for corneal preservation

-

, (2008/06/13)

A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements which maintains and enhances the preservation of eye tissues, including human corneal tissues at low temperatures (2° C. to 15° C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing components, antibiotic(s), ATP precursors and nutrient cell supplements.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 28002-70-2